Q-omics provides the consensus-scored TMCO1 profile across patient tissues and cancer cell-line models. TMCO1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMCO1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TMCO1 protein abundance shows 20,312 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, and CCRCC as cancer lineages where TMCO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMCO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMCO1 survival associations across molecular data types. TMCO1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMCO1 RNA expression–survival associations across cancer types. High TMCO1 expression shows unfavorable associations in HNSC, UVM, KIRP, ACC, SCLC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMCO1 RNA expression.
This table summarizes TMCO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMCO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMCO1 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BLCA, LIHC and LUAD. The HNSC box plot shows higher TMCO1 RNA expression in tumor versus normal tissue (log2 FC = +0.740, t-test p < 0.001).
This table shows molecular features associated with TMCO1 in patient tissues and cancer cell lines. In patient samples, TMCO1 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMCO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
